REPORT ID 4351

Global Oligodendroglioma Treatment Market Research Report 2017

Publish Date
18-Dec-17
Pages
118
Format
Electronic (PDF)

In this report, the global Oligodendroglioma Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Oligodendroglioma Treatment in these regions, from 2012 to 2022 (forecast), covering
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
Global Oligodendroglioma Treatment market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
    AngioChem Inc
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Co
    Cavion LLC
    Celldex Therapeutics Inc
    Eli Lilly and Co
    F. Hoffmann-La Roche Ltd
    Immatics Biotechnologies GmbH
    Ipsen SA
    Leadiant Biosciences Inc
    Millennium Pharmaceuticals Inc
    Northwest Biotherapeutics Inc
    Novartis AG
    Pfizer Inc
    Tocagen Inc
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Alisertib
    Bevacizumab
    CDX-1401
    Dasatinib
    DCVax-L
    IMA-950
    Others
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
    Clinic
    Hospital
    ASCs

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global Oligodendroglioma Treatment Market Research Report 2017
1 Oligodendroglioma Treatment Market Overview
    1.1 Product Overview and Scope of Oligodendroglioma Treatment
    1.2 Oligodendroglioma Treatment Segment by Type (Product Category)
        1.2.1 Global Oligodendroglioma Treatment Production and CAGR (%) Comparison by Type (Product Category)(2012-2022)
        1.2.2 Global Oligodendroglioma Treatment Production Market Share by Type (Product Category) in 2016
        1.2.3 Alisertib
        1.2.4 Bevacizumab
        1.2.5 CDX-1401
        1.2.6 Dasatinib
        1.2.7 DCVax-L
        1.2.8 IMA-950
        1.2.9 Others
    1.3 Global Oligodendroglioma Treatment Segment by Application
        1.3.1 Oligodendroglioma Treatment Consumption (Sales) Comparison by Application (2012-2022)
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 ASCs
    1.4 Global Oligodendroglioma Treatment Market by Region (2012-2022)
        1.4.1 Global Oligodendroglioma Treatment Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
        1.4.2 North America Status and Prospect (2012-2022)
        1.4.3 Europe Status and Prospect (2012-2022)
        1.4.4 China Status and Prospect (2012-2022)
        1.4.5 Japan Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Status and Prospect (2012-2022)
        1.4.7 India Status and Prospect (2012-2022)
    1.5 Global Market Size (Value) of Oligodendroglioma Treatment (2012-2022)
        1.5.1 Global Oligodendroglioma Treatment Revenue Status and Outlook (2012-2022)
        1.5.2 Global Oligodendroglioma Treatment Capacity, Production Status and Outlook (2012-2022)

2 Global Oligodendroglioma Treatment Market Competition by Manufacturers
    2.1 Global Oligodendroglioma Treatment Capacity, Production and Share by Manufacturers (2012-2017)
        2.1.1 Global Oligodendroglioma Treatment Capacity and Share by Manufacturers (2012-2017)
        2.1.2 Global Oligodendroglioma Treatment Production and Share by Manufacturers (2012-2017)
    2.2 Global Oligodendroglioma Treatment Revenue and Share by Manufacturers (2012-2017)
    2.3 Global Oligodendroglioma Treatment Average Price by Manufacturers (2012-2017)
    2.4 Manufacturers Oligodendroglioma Treatment Manufacturing Base Distribution, Sales Area and Product Type
    2.5 Oligodendroglioma Treatment Market Competitive Situation and Trends
        2.5.1 Oligodendroglioma Treatment Market Concentration Rate
        2.5.2 Oligodendroglioma Treatment Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Oligodendroglioma Treatment Capacity, Production, Revenue (Value) by Region (2012-2017)
    3.1 Global Oligodendroglioma Treatment Capacity and Market Share by Region (2012-2017)
    3.2 Global Oligodendroglioma Treatment Production and Market Share by Region (2012-2017)
    3.3 Global Oligodendroglioma Treatment Revenue (Value) and Market Share by Region (2012-2017)
    3.4 Global Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.5 North America Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.6 Europe Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.7 China Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.8 Japan Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.9 Southeast Asia Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.10 India Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Oligodendroglioma Treatment Supply (Production), Consumption, Export, Import by Region (2012-2017)
    4.1 Global Oligodendroglioma Treatment Consumption by Region (2012-2017)
    4.2 North America Oligodendroglioma Treatment Production, Consumption, Export, Import (2012-2017)
    4.3 Europe Oligodendroglioma Treatment Production, Consumption, Export, Import (2012-2017)
    4.4 China Oligodendroglioma Treatment Production, Consumption, Export, Import (2012-2017)
    4.5 Japan Oligodendroglioma Treatment Production, Consumption, Export, Import (2012-2017)
    4.6 Southeast Asia Oligodendroglioma Treatment Production, Consumption, Export, Import (2012-2017)
    4.7 India Oligodendroglioma Treatment Production, Consumption, Export, Import (2012-2017)

5 Global Oligodendroglioma Treatment Production, Revenue (Value), Price Trend by Type
    5.1 Global Oligodendroglioma Treatment Production and Market Share by Type (2012-2017)
    5.2 Global Oligodendroglioma Treatment Revenue and Market Share by Type (2012-2017)
    5.3 Global Oligodendroglioma Treatment Price by Type (2012-2017)
    5.4 Global Oligodendroglioma Treatment Production Growth by Type (2012-2017)

6 Global Oligodendroglioma Treatment Market Analysis by Application
    6.1 Global Oligodendroglioma Treatment Consumption and Market Share by Application (2012-2017)
    6.2 Global Oligodendroglioma Treatment Consumption Growth Rate by Application (2012-2017)
    6.3 Market Drivers and Opportunities
        6.3.1 Potential Applications
        6.3.2 Emerging Markets/Countries

7 Global Oligodendroglioma Treatment Manufacturers Profiles/Analysis
    7.1 AngioChem Inc
        7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.1.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.1.2.1 Product A
            7.1.2.2 Product B
        7.1.3 AngioChem Inc Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.1.4 Main Business/Business Overview
    7.2 Boehringer Ingelheim GmbH
        7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.2.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.2.2.1 Product A
            7.2.2.2 Product B
        7.2.3 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.2.4 Main Business/Business Overview
    7.3 Bristol-Myers Squibb Co
        7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.3.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.3.2.1 Product A
            7.3.2.2 Product B
        7.3.3 Bristol-Myers Squibb Co Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.3.4 Main Business/Business Overview
    7.4 Cavion LLC
        7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.4.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.4.2.1 Product A
            7.4.2.2 Product B
        7.4.3 Cavion LLC Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.4.4 Main Business/Business Overview
    7.5 Celldex Therapeutics Inc
        7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.5.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.5.2.1 Product A
            7.5.2.2 Product B
        7.5.3 Celldex Therapeutics Inc Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.5.4 Main Business/Business Overview
    7.6 Eli Lilly and Co
        7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.6.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.6.2.1 Product A
            7.6.2.2 Product B
        7.6.3 Eli Lilly and Co Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.6.4 Main Business/Business Overview
    7.7 F. Hoffmann-La Roche Ltd
        7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.7.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.7.2.1 Product A
            7.7.2.2 Product B
        7.7.3 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.7.4 Main Business/Business Overview
    7.8 Immatics Biotechnologies GmbH
        7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.8.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.8.2.1 Product A
            7.8.2.2 Product B
        7.8.3 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.8.4 Main Business/Business Overview
    7.9 Ipsen SA
        7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.9.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.9.2.1 Product A
            7.9.2.2 Product B
        7.9.3 Ipsen SA Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.9.4 Main Business/Business Overview
    7.10 Leadiant Biosciences Inc
        7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.10.2 Oligodendroglioma Treatment Product Category, Application and Specification
            7.10.2.1 Product A
            7.10.2.2 Product B
        7.10.3 Leadiant Biosciences Inc Oligodendroglioma Treatment Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.10.4 Main Business/Business Overview
    7.11 Millennium Pharmaceuticals Inc
    7.12 Northwest Biotherapeutics Inc
    7.13 Novartis AG
    7.14 Pfizer Inc
    7.15 Tocagen Inc

8 Oligodendroglioma Treatment Manufacturing Cost Analysis
    8.1 Oligodendroglioma Treatment Key Raw Materials Analysis
       8.1.1 Key Raw Materials
       8.1.2 Price Trend of Key Raw Materials
       8.1.3 Key Suppliers of Raw Materials
       8.1.4 Market Concentration Rate of Raw Materials
    8.2 Proportion of Manufacturing Cost Structure
       8.2.1 Raw Materials
       8.2.2 Labor Cost
       8.2.3 Manufacturing Expenses
    8.3 Manufacturing Process Analysis of Oligodendroglioma Treatment

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
    9.1 Oligodendroglioma Treatment Industrial Chain Analysis
    9.2 Upstream Raw Materials Sourcing
    9.3 Raw Materials Sources of Oligodendroglioma Treatment Major Manufacturers in 2015
    9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
    10.1 Marketing Channel
        10.1.1 Direct Marketing
        10.1.2 Indirect Marketing
        10.1.3 Marketing Channel Development Trend
    10.2 Market Positioning
        10.2.1 Pricing Strategy
        10.2.2 Brand Strategy
        10.2.3 Target Client
    10.3 Distributors/Traders List

11 Market Effect Factors Analysis
    11.1 Technology Progress/Risk
        11.1.1 Substitutes Threat
        11.1.2 Technology Progress in Related Industry
    11.2 Consumer Needs/Customer Preference Change
    11.3 Economic/Political Environmental Change

12 Global Oligodendroglioma Treatment Market Forecast (2017-2022)
    12.1 Global Oligodendroglioma Treatment Capacity, Production, Revenue Forecast (2017-2022)
        12.1.1 Global Oligodendroglioma Treatment Capacity, Production and Growth Rate Forecast (2017-2022)
        12.1.2 Global Oligodendroglioma Treatment Revenue and Growth Rate Forecast (2017-2022)
        12.1.3 Global Oligodendroglioma Treatment Price and Trend Forecast (2017-2022)
    12.2 Global Oligodendroglioma Treatment Production, Consumption , Import and Export Forecast by Region (2017-2022)
        12.2.1 North America Oligodendroglioma Treatment Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.2 Europe Oligodendroglioma Treatment Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.3 China Oligodendroglioma Treatment Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.4 Japan Oligodendroglioma Treatment Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.5 Southeast Asia Oligodendroglioma Treatment Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.6 India Oligodendroglioma Treatment Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
    12.3 Global Oligodendroglioma Treatment Production, Revenue and Price Forecast by Type (2017-2022)
    12.4 Global Oligodendroglioma Treatment Consumption Forecast by Application (2017-2022)

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology/Research Approach
        14.1.1 Research Programs/Design
        14.1.2 Market Size Estimation
        14.1.3 Market Breakdown and Data Triangulation
    14.2 Data Source
        14.2.1 Secondary Sources
        14.2.2 Primary Sources
    14.3 Disclaimer